Cure My Disease

Don't miss your cure!

 Log in / Sign up

Multi-Agent collaborative framework for adverse drug reaction prediction: Evidence-Based verification and Human-Machine decision comparative study

NCT ID NCT07808866

NEW Sponsor: Peking University Third Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 09, 2026 · Last updated Sep 09, 2026

Summary

This study develops a multi-agent collaborative prediction model to forecast adverse drug reactions using real-world clinical medical records. It validates model performance via evidence-based data and compares decision outputs between the AI model and clinical physicians, aiming to improve early identification of drug adverse events. Only de-identified historical medical data will be analyzed; no new clinical interventions will be conducted, with no additional risks to participants.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 20,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study includes two types of research subjects: Retrospective de-identified adverse drug reaction (ADR) medical records: A total of 253 ADR consultation cases covering anti-infectives, cardiovascular agents, anti-tumor drugs, central nervous system drugs and digestive system drugs. Each case contains complete medical history, medication records, ADR occurrence process and clinical outcome data, as well as at least one clinically confirmed definite ADR event. Clinical evaluators: 20 licensed physicians or pharmacists holding intermediate or higher professional titles, with clinical pharmacy practice and regular participation in hospital ADR monitoring and consultation work.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Cases shall involve drug categories including anti-infectives, cardiovascular agents, anti-tumor drugs, central nervous system drugs, digestive system drugs, etc. Each case must contain at least one definite adverse drug reaction (ADR) event, with complete supporting documentation (medical history, medication history, ADR occurrence process, and clinical outcome). Exclusion Criteria: * Cases with incomplete supporting documentation lacking medical history, medication history, ADR occurrence process or clinical outcome. * Cases only with suspected or possible ADRs without definite clinical confirmation.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adverse drug reactions are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Drug-Related Side Effects and Adverse Reactions

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Adverse drug reactions Clinical decision support

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University Third Hospital

    RECRUITING

    Beijing, Beijing Municipality, China

  • Peking University Third Hospital

    NOT_YET_RECRUITING

    Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.